| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J |
NCT00210717: A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia |
|
|
| Completed | 3 | 748 | US | paliperidone palmitate | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 04/07 | | |
NCT00589914: Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia |
|
|
| Completed | 3 | 1221 | US, Europe, RoW | RISPERDAL CONSTA, Paliperidone palmitate | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 06/09 | 06/09 | | |
NCT01299389: An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia |
|
|
| Completed | 3 | 323 | Japan, RoW | Paliperidone palmitate, Placebo | Janssen Pharmaceutical K.K. | Schizophrenia | 05/12 | 05/12 | | |
NCT01258920: A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia |
|
|
| Completed | 3 | 201 | Japan | Paliperidone palmitate | Janssen Pharmaceutical K.K. | Schizophrenia | 11/12 | 11/12 | | |
| Completed | 3 | 769 | Europe, RoW | paliperidone palmitate injection, oral antipsychotics | Janssen-Cilag International NV | Schizophrenia | 02/13 | 02/13 | | |
NCT01051531: A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia |
|
|
| Completed | 3 | 546 | RoW | Paliperidone palmitate | Johnson & Johnson Pte Ltd | Schizophrenia | 05/13 | 05/13 | | |
NCT01193153: A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder |
|
|
| Completed | 3 | 667 | US, Europe, RoW | Placebo, paliperidone palmitate | Janssen Scientific Affairs, LLC | Schizoaffective Disorder | 10/13 | 10/13 | | |
| Completed | 3 | 295 | US | Aripiprazole and aripiprazole once-monthly, Aripiprazole: Abilify®, Aripiprazole (extended-release injectable suspension): Abilify Maintena®, Paliperidone and paliperidone palmitate, Paliperidone: Invega®, Paliperidone palmitate: Xeplion® or Invega® Sustenna® | H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd. | Schizophrenia | 09/14 | 09/14 | | |
| Completed | 3 | 1429 | Japan, US, Canada, Europe, RoW | PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq., PP3M 525 mg eq., Placebo (20% Intralipid), PP1M 50 mg eq., PP1M 75 mg eq., PP1M 100 mg eq., PP1M 150 mg eq. | Janssen Research & Development, LLC | Schizophrenia | 02/15 | 03/15 | | |
